55745-35-2

Usage

Chemical class

Piperazine derivatives

Receptor specificity

Potent and selective 5-HT1A receptor agonist

Function

Binds to and activates serotonin receptors in the brain

Therapeutic potential

Treatment of psychiatric and neurological disorders

Specific disorders

Anxiety, depression, and Parkinson's disease

Additional properties

Demonstrated neuroprotective properties

Current status

Promising candidate for new medications

Further research

Required to understand potential benefits and safety profile

Clinical trials

Necessary for medical application evaluation

InChI:InChI=1/C16H19N3OS.ClH/c1-2-15-14(3-9-20-15)11-13(1)12-18-5-7-19(8-6-18)16-17-4-10-21-16;/h1-2,4,10-11H,3,5-9,12H2;1H

Upstream product

• 3034-52-4 2-chlorothiazole 
• 55745-69-2 1-(5-coumaranyl methyl) piperazine 

Relevant academic research and scientific papers

A new central direct dopaminergic stimulant: 1 (coumaran 5 yl methyl) 4 (2 thiazolyl) piperazine hydrochloride (S 3608)

The central stimulating effect of S 3608 in the rat induced a stereotyped behavioural response, similar to that of apomorphine. The intensity of stimulation was self limited and increasing the dosage of S 3608 above 40 mg/kg did not modify the response. The stereotyped response was only enhanced in higher doses in the case of apomorphine. On the contrary, these changes were not observed with S 3608 indicating the central stimulant effect is different in nature or intensity. S 3608 and Piribedil induced turning in rats, contralateral to a lesion in the substantia nigra. The 2 compounds have a sustained effect, the central dopaminergic stimulant potency being comparable. S 3608 exerted a delay on the onset of morphine catatonia, modifying the ED50 of the analgesic. Ergocornine an CB 154 behaved as powerful antagonists on morphine catatonia, the former compound inducing peripheral neurovegetative signs, but the antagonistic effect of CB 154 was observed without any vegetative signs. Yohimbine modified the morphine rigidity, indicating that a block of the central sympathetic activity may be detected in the morphine model, as well as a strong direct dopaminergic stimulant effect. The data support the hypothesis that S 3608 is a new direct central dopamine stimulant, different from apomorphine, qualitatively and quantitatively. In the rotation model, the potency of stimulation is similar to that of Piribedil. Further experiments are in progress to elucidate the mechanism of action of S 3608 on central dopaminergic and noradrenergic mechanisms.

N-Coumaranyl and chromanyl -methyl-or sulfur analogs thereof-N'- thiazolyl piperazines

Disubstituted piperazines of the formula: SPC1 Wherein: n is 1 or 2; X is oxygen or sulfur; R is hydrogen or lower alkyl; Het is pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolyl, quinazolyl, thiazolyl or benzothiazolyl, each optionally substituted by one or more lower alkyl, lower alkoxy, phenyl, amino, mono or di-lower-alkylamino, or hydroxy, and, SPC2 Is always bonded to the benzene ring. These compounds are used as medicines especially in the treatment of peripheral vascular disorders, Parkinson's disease, hypertension and as antipregnancy drugs.